Skip to content

Fig fruit extract cream and hydrocortisone ointment in atopic dermatitis

Clinical trials for comparison between the efficacy of the fig fruit extract cream, hydrocortisone ointment and placebo on the severity of skin lesions in children up to 15 years of age with mild to moderate atopic dermatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014101419529N1
Enrollment
45
Registered
2015-03-11
Start date
2015-02-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis. Atopic Dermatitis

Interventions

Intervention 1: Patients in intervention group should use the fig fruit extract cream twice daily for 2 weeks on all cutaneous lesions of the whole body. Intervention 2: Patients in control group shou
Treatment - Drugs
Patients in intervention group should use the fig fruit extract cream twice daily for 2 weeks on all cutaneous lesions of the whole body.
Patients in control group should use hydrocortisone ointment twice daily for 2 weeks on all cutaneous lesions of the whole body.
Patients in placebo group should use Farabi base cream twice daily for 2 weeks on all cutaneous lesions of the whole body.

Sponsors

Vice chancellor for research of Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Days to 15 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Children up to 15 years of age with mild to moderate atopic dermatitis exclusion criteria: 1- Children with severe atopic dermatitis. 2- Children with systemic disease, other skin disease, immune deficiency or skin infections. 3- Users of systemic drugs during last 4 weeks or topical drugs during last 2 weeks for atopic dermatitis treatment. 4- Patients who do not desired to stay in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Clinical severity of cutaneous lesions. Timepoint: At baseline, at the end of the treatment course(2 weeks later), one month after the cessation of the treatment. Method of measurement: SCORAD index.

Secondary

MeasureTime frame
Recurrence of cutaneous lesions. Timepoint: 1 month after the cessation of the treatment. Method of measurement: Physical exam and history taking.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShirin Abbasi

Faculty of Traditional Medicine

abbasish931@mums.ac.ir, shirinabbasi.md@gmail.com+98 51 3855 2188

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026